- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Interventions
- Donanemab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more
Alzheimer's Disease clinical trials
Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 8, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Alzheimer's Disease studies are organized in the registry
The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
- Interventions
- ATTN201 Focused Ultrasound to the CMN, ATTN201 Unfocused Ultrasound
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Interventions
- 18F-PF974, 18F-florbetaben
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alzheimer's Disease
- Interventions
- KarXT, KarX-EC, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 31
- States / cities
- Fullerton, California • Irvine, California • Los Angeles, California + 28 more
- Conditions
- Alzheimers Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nutley, New Jersey
- Conditions
- Early Alzheimer's Disease
- Interventions
- MK-2214, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 36
- States / cities
- Irvine, California • Long Beach, California • Los Angeles, California + 32 more
- Conditions
- Alzheimer's Disease
- Interventions
- Psilocybin, Cognitive Training
- Drug · Other
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 65 Years to 120 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease
- Interventions
- Insulin (Humulin® R U-100), Empagliflozin 10 MG, Aptar Pharma CPS Intranasal Delivery Device, Placebo (Insulin Diluent), Placebo (Capsules)
- Drug · Device
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Alzheimer's Disease
- Interventions
- Remternetug, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 108 more
- Conditions
- Alzheimer's Disease
- Interventions
- KarXT, KarX-EC, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 28
- States / cities
- Long Beach, California • Redlands, California • Basalt, Colorado + 24 more
- Conditions
- Alzheimer s Disease, MCI With Increased Risk for Alzheimer Disease
- Interventions
- Ultrasonic Debris Clearance, sham
- Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2031
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
About this Alzheimer's Disease clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.